UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study

PLoS medicine, 2021-05, Vol.18 (5), p.e1003620-e1003620

2021

Volltextzugriff (PDF)

Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: Disease Progression and Survival Analysis From Four Randomized, Double-Blind, Placebo-Controlled Trials

Journal of clinical oncology, 2005-10, Vol.23 (28), p.6941-6948

2005

Volltextzugriff (PDF)

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

BMC cancer, 2011-07, Vol.11 (1), p.313-313, Article 313

2011

Volltextzugriff (PDF)

Effects of a prescribed, supervised exercise programme on tumour disease progression in oncology patients undergoing anti‐cancer therapy: a retrospective observational cohort study

Internal medicine journal, 2023-01, Vol.53 (1), p.104-111

2023

Volltextzugriff (PDF)

Early cardiac changes following anthracycline chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers

Journal of cardiovascular magnetic resonance, 2012-02, Vol.14 (S1), p.P181-P181, Article P181

2012

Volltextzugriff (PDF)

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas

Journal of clinical oncology, 2015-12, Vol.33 (36), p.4276-4283

2015

Volltextzugriff (PDF)

First-in-human (FIH) trial evaluating immune activation and safety of PIN- 2 administered intravenously to patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2600-2600

2019

Volltextzugriff (PDF)

Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study

Cancer, 2024-06, Vol.130 (11), p.1991-2002

2024

Volltextzugriff (PDF)

Response to erlotinib in a patient with treatment refractory chordoma

Anti-cancer drugs, 2009-11, Vol.20 (10), p.953-955

2009

Volltextzugriff (PDF)

Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers

International journal of cardiology, 2013-10, Vol.168 (6), p.5465-5467

2013

Volltextzugriff (PDF)

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer

British journal of cancer, 2023-11, Vol.129 (10), p.1608-1618

2023

Volltextzugriff (PDF)

A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14006-e14006

2019

Volltextzugriff (PDF)

Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma

ANZ journal of surgery, 2017-07, Vol.87 (7-8), p.E48-E49

2017

Volltextzugriff (PDF)

Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.710-710

2020

Volltextzugriff (PDF)

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

Investigational new drugs, 2018-12, Vol.36 (6), p.1060-1071

2018

Volltextzugriff (PDF)

Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2021-09, Vol.159, p.162-170

2021

Volltextzugriff (PDF)

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

Targeted oncology, 2018-02, Vol.13 (1), p.89-98

2018

Volltextzugriff (PDF)

A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16231-e16231

2018

Volltextzugriff (PDF)

Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.648-648

2018

Volltextzugriff (PDF)

Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease

Molecular medicine (Cambridge, Mass.), 1995-11, Vol.1 (7), p.789-794

1995

Volltextzugriff (PDF)

Unexplained bloody pericardial effusion: a diagnostic dilemma

European heart journal cardiovascular imaging, 2015-05, Vol.16 (5), p.573-573

2015

Volltextzugriff (PDF)

Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2558-2558

2019

Volltextzugriff (PDF)

Epidemiology of neuroendocrine cancers in an Australian population

Cancer causes & control, 2010-06, Vol.21 (6), p.931-938

2010

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(70)
Berichte
(2)

Sprache

Englisch
(72)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study

Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib

Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: Disease Progression and Survival Analysis From Four Randomized, Double-Blind, Placebo-Controlled Trials

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

Effects of a prescribed, supervised exercise programme on tumour disease progression in oncology patients undergoing anti‐cancer therapy: a retrospective observational cohort study

Early cardiac changes following anthracycline chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers

First-in-human (FIH) trial evaluating immune activation and safety of PIN- 2 administered intravenously to patients with advanced solid tumors

Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study

Response to erlotinib in a patient with treatment refractory chordoma

Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer

A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105

Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma

Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA)

Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study)

Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease

Unexplained bloody pericardial effusion: a diagnostic dilemma

Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study

Epidemiology of neuroendocrine cancers in an Australian population

Suchergebnisse filtern